Clinical trials: Immunity to COVID-19
COVID-19, Immune Response
Immunomodulatory Effect of Probiotics on the Immunogenicity of Anti-SARS-CoV-2 Vaccines
This study aims to evaluate whether oral probiotic supplementation can modulate the immune response induced by COVID-19 vaccination.
- Trial name
- NCT07610512
- Testing
- Probiotics
- Where
- Taiwan
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Grape King Bio Ltd.
Immunization
Adjuvant Effect of Physical Exercise on Immune Response to COVID-19 Vaccination and Interactions With Stress
The purpose of this study is to evaluate the extent to which a single session of light to moderate intensity exercise performed within 30 minutes after receiving either the initial dose of COVID-19 mRNA vaccine may modify the…
- Trial name
- NCT05213000
- Testing
- Exercise
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Iowa State University
COVID-19
Evaluating the Response of the Immune System of People With Long COVID (Post SARS-CoV-2)
Many people who have had COVID 19 continue to experience symptoms long after they have recovered from the acute infection. This study will examine the clinical symptoms of people with "Long COVID" and measure various markers of…
- Trial name
- LCRC (NCT05131594)
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Huntington Memorial Hospital
Influenza, Human+COVID-19
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection.
- Trial name
- NCT07464314
- Testing
- Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine, Licensed Seasonal Influenza Vaccine, Licensed COVID-19 Vaccine
- Where
- 12 sites in United States
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis, Covid19
Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients
This non-interventional, biospecimen collection study is designed to help us better understand whether MS patients have impaired immune defenses to COVID-19 infection.
- Trial name
- NCT04682548
- Where
- United States
- Volunteers
- 920 people
- Sponsor
- NYU Langone Health
COVID-19, SARS-CoV-2
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
- Trial name
- NOVELLA (NCT06057064)
- Testing
- Biological: AZD3152
- Where
- 6 sites in Russia
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
Covid19, Haematological Disorders
Covid-19 Vaccine Response in Immunocompromised Haematology Patients
The UK Medicine and Healthcare products Regulatory Agency (MHRA) granted temporary authorisation to three Covid-19 vaccines in December 2020 and January 2021.
- Conditions
- Covid19, Haematological Disorders, Immune Suppression
- Trial name
- COVAC-IC (NCT04805216)
- Testing
- Blood test
- Where
- United Kingdom
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
SARS-CoV-2
Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19)
A total of 300 healthy volunteers between the ages of 18 and 80 with no previous history of COVID-19 will be entered into the study and will receive IPV by injection on Day 1.
- Trial name
- NCT04639375
- Testing
- Vaccinated with polio vaccine (IPV)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- E-MO Biology Inc
SARS-CoV-2 Infection, Coronavirus Disease 2019 (COVID-19)
COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older
The most recently discovered coronavirus (SARS-CoV-2) may cause illness in humans ranging from the common cold to serious illness, also referred to as Coronavirus disease 2019 (COVID-19).
- Trial name
- CV-NCOV-011 (NCT04848467)
- Testing
- SARS-CoV-2 mRNA Vaccine (CVnCoV), Quadrivalent influenza vaccine (QIV)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bayer
Corona Virus Infection, Flu Vaccine
Understanding Immunity to the Flu Vaccine in COVID-19 Patients
The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19…
- Conditions
- Corona Virus Infection, Flu Vaccine, Immunity
- Trial name
- NCT04579588
- Testing
- Flu shot
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Stanford University
Healthy Older Adults Ages 60-89
Longitudinal Innate Immunity and Aging Study
This study plans to examine biological bases of cognitive aging. The goals of the study are to better understand how immune system markers, measured in the blood and in the spinal fluid, are related to clinical features of aging…
- Trial name
- LIIA (NCT03944603)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Sarcoidosis, SARS-CoV2 Infection
Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis
People with sarcoidosis, particularly those with significant lung and/or cardiac involvement, who become infected with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) are likely at increased risk of complications or…
- Conditions
- Sarcoidosis, SARS-CoV2 Infection, Vaccine Response Impaired
- Trial name
- NCT05089565
- Testing
- Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Herpes Zoster
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent…
- Trial name
- NCT05047770
- Testing
- HZ/su, Flu D-QIV, mRNA-1273
- Where
- 46 sites in United States
- Volunteers
- 2,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, Immunosuppression
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
Immunocompromised individuals, such as solid organ transplant (SOT) recipients are at high risk of COVID-19 associated complications and mortality.
- Conditions
- COVID-19, Immunosuppression, Vaccine Response Impaired
- Trial name
- ADIVKT (NCT05060991)
- Testing
- Reduction in antimetabolite immunosuppression
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, Davis
Hematologic Diseases
Evaluation of the Immune Response to Sars-Covid-19 Vaccines in Haematological Patients: Prospective Single Center Study
The main objective of this study is to investigate the humoral immune response to COVID-19 vaccines in haematological patients, by testing SARS-CoV-2 seroconversion
- Trial name
- Hema-C19-Vax (NCT05074706)
- Testing
- IgG antibodies to Sars-Cov-2, QuantiFERON SARS-CoV-2 test
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- University of Milano Bicocca
SARS-CoV-2, COVID-19
A Study of Immune Responses to the Virus That Causes COVID-19
The purpose of this study is to learn more about the acute response to infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- CoVPN 5001 (NCT04431414)
- Testing
- Sample collection
- Where
- 52 sites in United States, Argentina and 9 more
- Volunteers
- 953 people
- Sponsor
- COVID-19 Prevention Network
COVID - 19
Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers
This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration…
- Trial name
- NCT06831786
- Testing
- Bivalent mRNA SARS-CoV-2 vaccine, Quardrivalent influenza vaccine
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Prince of Songkla University
COVID-19
Correlation Study of Isotype Switching and Neutralizing Capacity to the COVID-19 Variants Strain
The level of neutralizing antibody was detected by using the constructed pseudovirus covid-19 variant at baseline , 1 month , 6 months and 12 months after primary vaccination, within 15 days after booster immunization at 12…
- Trial name
- NCT05087277
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
COVID-19
Predictive Immune Biomarkers for COVID-19 Pathogenesis
The spectrum of the COVID-19 disease ranges from benign to asymptomatic to viral pneumopathy that can progress to acute respiratory distress syndrome (ARDS).
- Trial name
- COVIDBioToul (NCT04385108)
- Testing
- Blood collection on admission and longitudinally, Blood collection on their first consultation and 10 to 14 days later
- Where
- France
- Volunteers
- 565 people
- Sponsor
- University Hospital, Toulouse
Covid19
Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays
The primary objective is to assess the ability of COVID-19 IgG and IgM assays to detect an immune response in COVID-19 patients in the Henry Ford Health System (HFHS), both during hospitalization and over the following 12 months.
- Trial name
- NCT04562285
- Testing
- Serologic immunoassays to SARS-CoV-2 antibodies
- Where
- United States
- Volunteers
- 829 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System